What happened with RDHL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
RedHill Biopharma primarily advances clinical-stage medicines for gastrointestinal diseases, infectious diseases and cancer. Its candidates are not yet approved for sale. Hyloris Pharmaceuticals pays RedHill for rights to develop and commercialize RHB-102, also called Bekinda, outside the United States, Canada and Mexico. That license generates income through minimum annual payments, with additional payments tied to commercial targets and royalties on sales, subject to certain cost deductions.
RedHill also participates in sales of Talicia, an oral treatment approved in the United States for H. pylori infection in adults. It no longer sells Talicia directly: Talicia Holdings holds the global rights, and RedHill retains majority ownership but shares control with Cumberland. Cumberland supplies the U.S. sales organization and distribution, while Talicia Holdings supplies the medicine and bears manufacturing costs. The two companies share U.S. net revenue; RedHill’s benefit depends on Talicia Holdings’ performance and available cash.
Talicia’s business depends heavily on Cumberland, insurance reimbursement and third-party manufacturers. The development pipeline needs regulatory approval before its medicines can be marketed. RedHill also needs substantial additional funding: its available resources are insufficient to sustain operations, and management has expressed substantial doubt about its ability to continue operating.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
RedHill's results hinge on clinical-pipeline progress, Talicia partnership economics and Hyloris Pharmaceuticals' development and commercialization of licensed Bekinda outside North America.
RedHill's Talicia cash flows depend heavily on Cumberland Pharmaceuticals Inc, which sells and distributes the prescription medicine in the U.S.; the companies jointly control Talicia Holdings, which shares U.S. Talicia net revenues equally with Cumberland. Watch Cumberland's Talicia sales and commercialization spending: RedHill's benefit depends on Talicia Holdings' performance and cash position through its 70% stake.
Phathom Pharmaceuticals, Inc. competes directly with RedHill's Talicia for U.S. sales of medicines treating adult H. pylori infection through its VOQUEZNA DUAL PAK and TRIPLE PAK. Watch sales of those two treatment packs rather than total VOQUEZNA revenue, which also includes tablets used for other conditions.
Cumberland Pharmaceuticals Inc earningsCPIX
Cumberland Pharmaceuticals sells and distributes Talicia in the U.S., and its report will show whether that business is supporting the Talicia Holdings stake RedHill Biopharma owns.
Read Cumberland’s Talicia sales alongside its commercialization spending, then consider Talicia Holdings’ cash position. Rising sales with controlled spending would leave the jointly owned business better able to retain cash, supporting the value RedHill can receive through its 70% stake. Weak sales, or spending that grows faster than sales, would strain the cash available to support the business and reduce RedHill’s potential benefit from that stake.
